Maze Therapeutics vs Tempus
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision Medicine — Renal, Cardiovascular & Metabolic Diseases
Maze Therapeutics is a clinical-stage precision medicine company using human genetics to develop small-molecule drugs for chronic kidney disease and obesity; lead programs MZE829 and MZE782 in Phase 1/2;
About
Maze Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 by Charles Homcy and headquartered in South San Francisco, California, that uses human genetics as its primary drug discovery engine. The company's approach begins with population-scale genetic data to identify individuals who are naturally protected from diseases like chronic kidney disease (CKD), obesity, and cardiovascular disorders — then designs small-molecule drugs that mimic the protective genetic effect in the broader patient population. This genetics-first model is designed to increase the probability of clinical success by targeting validated mechanisms with demonstrated human proof of concept before any clinical trial begins.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
About
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.